Sensei Biotherapeutics, Inc.(FTH)Stock Analysis
AI analysis on 6,000+ stocks →Deep AI analysis on 6,000+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
FTH Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Sensei Biotherapeutics, Inc. (FTH), a Healthcare sector company. FTH is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings, Sensei Biotherapeutics, Inc. reports net income of $-170.2M, free cash flow of $-10.7M. Top institutional holders of FTH by reported 13-F value include Vivo Capital,, Woodline Partners, Cormorant Asset Management,, based on the most recent SEC filings. FTH trades on the Nasdaq exchange and files with the SEC under CIK 1829802. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate FTH daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Sensei Biotherapeutics, Inc. directly from SEC EDGAR.
Net Income
Q1 2026
$-170.2M
Free Cash Flow
Q1 2026
$-10.7M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Net Income
+30.1% YoYOperating Income
+31.7% YoYEPS (Diluted)
+30.4% YoYTotal Assets
-49.5% YoYTotal Debt
Op. Cash Flow
+17.1% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Income | $-21.1M +30.1% | $-30.2M +11.6% | $-34.1M +29.8% | $-48.6M -32.1% | $-36.8M |
| Operating Income | $-22.3M +31.7% | $-32.6M +12.0% | $-37.1M +26.1% | $-50.2M -33.9% | $-37.5M |
| EPS (Diluted) | $-16.72 +30.4% | $-24.01 -1868.0% | $-1.22 +22.8% | $-1.58 | — |
| Total Assets | $22.9M -49.5% | $45.4M -39.0% | $74.4M -37.2% | $118.4M -22.7% | $153.2M |
| Total Debt | — | — | — | — | $567.0K |
| Operating Cash Flow | $-20.5M +17.1% | $-24.7M +23.0% | $-32.0M +17.9% | $-39.0M -29.0% | $-30.3M |
Track FTH with AI-powered research
10 AI analysts debate this stock daily. Free to start.
Available Research
13F Pro tracks comprehensive data for Sensei Biotherapeutics, Inc. including:
Top Institutional Holders of FTH
Vivo Capital, LLC
$22.8M722,020 shWoodline Partners LP
$11.4M361,010 shCormorant Asset Management, LP
$9.7M306,222 shMILLENNIUM MANAGEMENT LLC
$4.6M146,565 shFRANKLIN RESOURCES INC
$4.2M133,506 shSTEMPOINT CAPITAL LP
$4.2M132,873 shCaligan Partners LP
$4.0M126,002 shTrails Edge Capital Partners, LP
$3.9M125,000 shNewtyn Management, LLC
$2.3M1,540,920 shNewtyn Management, LLC
$2.1M1,827,240 sh
| Fund | Value | Shares |
|---|---|---|
| Vivo Capital, LLC | $22.8M | 722,020 |
| Woodline Partners LP | $11.4M | 361,010 |
| Cormorant Asset Management, LP | $9.7M | 306,222 |
| MILLENNIUM MANAGEMENT LLC | $4.6M | 146,565 |
| FRANKLIN RESOURCES INC | $4.2M | 133,506 |
| STEMPOINT CAPITAL LP | $4.2M | 132,873 |
| Caligan Partners LP | $4.0M | 126,002 |
| Trails Edge Capital Partners, LP | $3.9M | 125,000 |
| Newtyn Management, LLC | $2.3M | 1,540,920 |
| Newtyn Management, LLC | $2.1M | 1,827,240 |
More Healthcare Companies
View all Healthcare →Unlock Full Research for FTH
Get detailed financial analysis, insider activity, institutional flows, AI-powered debates, and quality rankings for Sensei Biotherapeutics, Inc. and 6,000+ other companies.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is FTH a good stock to buy?
13F Pro's AI-powered analysis of Sensei Biotherapeutics, Inc. (FTH) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for FTH are available on the FTH stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own FTH?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling FTH. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Sensei Biotherapeutics, Inc.'s investment landscape.